Crystal Bridge Announces Receipt by Alpha Cognition of Japanese Patent for Alzheimer Drug Alpha-1062 and Announces Private Placement Updates
Crystal Bridge Enters into Arrangement Agreement with Alpha Cognition, Announces up to $13 Million Private Placement
Crystal Bridge Enterprises Announces Letter of Intent for Qualifying Transaction with Alpha Cognition Inc.
Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for its Progranulin Platform
Linical and Alpha Cognition Announce Strategic Partnership to Position Alpha- 1062 for Approval in the Unites States and Japan Alzheimer’s Markets